Victoria L. Bae-Jump, MD, PhD, is a UNC Lineberger Comprehensive Cancer Center member specializing in gynecologic oncology and procedures, translational research in ovarian and endometrial cancer, and novel therapeutics for endometrial cancer.
MD, PhD Professor, OBGYN-GYN Oncology Director, UNC Center for Women’s Health Research Associate Director, UNC Lineberger Diversity, Equity and Inclusion UNC-Chapel Hill Cancer Epidemiology Gynecologic Oncology Program Meet Wendy Brewster Area of Interest I am a co-investigator for several projects designed to identify populations at risk for disparate treatment and poor outcomes in endometrial, colon, … Read more
Two UNC researchers design a biological test to individualize chemotherapy.
While ultrasound provides a less expensive and radiation-free alternative to detecting and monitoring cancer compared to technologies such as X-rays, CT scans and MRIs, the lower clarity and resolution of ultrasound has limited its use in cancer treatment. Researchers at the University of North Carolina at Chapel Hill have overcome this limitation by combining ultrasound with a contrast agent comprised of micro-sized bubbles that pair with an antibody produced at elevated levels by many cancers.
Stella Waugh, who was diagnosed with ovarian cancer in 2011, was thankful to have family together for her first Thanksgiving as a survivor. She said their big family on Thanksgiving day, which brings together nine grandchildren, ex-spouses who are now friends, and all of their children, is real. It’s the American family. April Dudash of the Herald-Sun reports.
William Zamboni, PharmD, PhD, has developed a probe to measure the body’s immune function to help physicians deliver accurate, individualized doses for cancer patients prescribed nanoparticle-based drugs
Help her reach her 2,000-hat goal by December 16.
Charles Perou’s test can help patients decide on a course of treatment.
Q&A with UNC Lineberger members James P. Evans, MD, PhD; David Ollila, MD; Paola Gehrig, MD; and Keith D. Amos, MD, FACS.
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
